Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Northrop Grumman Corporation (NOC) vs Zoetis Inc (ZTS) Price & Performance

Northrop Grumman CorporationTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Northrop Grumman Corporation vs Zoetis Inc — how do they compare? Northrop Grumman Corporation trades at $578.56 (market cap $81.78B), while Zoetis Inc trades at $73.5 (market cap $31.14B). The key difference: Northrop Grumman Corporation is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.

NOCZTS
Market Cap
$81.78B$31.14B
Sector
IndustrialsHealth
52-Week High
$768.02$156.76
52-Week Low
$496.02$71.91
Enterprise Value
$95.77B$38.70B
Dividend Yield
1.63%2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Northrop Grumman Corporation

Northrop Grumman (NOC) trades at $577.12, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $7.68, and raised full-year guidance, supported by a record $105 billion backlog. Revenue growth is steady, with 2026 projected at $42.9 billion, and profitability remains solid with a net income margin of 10.48%.

The outlook is positive, driven by strategic contracts like the $7.6 billion Sentinel program and defense spending tailwinds. Risks include margin pressures from specific programs and geopolitical uncertainties. Analysts are bullish with a consensus price target of $598.57, suggesting upside potential from current levels.

Zoetis Inc

Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.

The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Northrop Grumman Corporation

Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.

Read more on NOC

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS